Sera Prognostics Inc (SERA)

NASD · Healthcare · Medical Devices · USA

Sera Prognostics Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.

Sera Prognostics is a women's health company that develops and commercializes blood-based biomarker tests and predictive analytics for pregnancy using proteomics and bioinformatics. Its first product, the PreTRM test, predicts the risk of preterm birth in pregnant women during early gestation. The company serves pregnant women, physicians, and healthcare payers seeking to improve maternal and neonatal health outcomes.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Sera Prognostics Inc stock.

Our verdict on SERA

Overvalued: intrinsic value $1.03 per share, market price $2.00, margin of safety -94.5% (as of 2026-11-17).

A 0.8x revenue multiple, discounted for its losses, values the shares at $1.03; the price of $2.00 is 94% above that value.

ETFs with the most weight in SERA

2 more funds hold it; the full list is part of the paid plan.

More on SERA

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than SERA in Medical Devices

37 more in this industry show a wider margin of safety.

Is SERA undervalued or overvalued?

SERA is overvalued (as of the 2026-11-17 close). A 0.8x revenue multiple, discounted for its losses, values the shares at $1.03; the price of $2.00 is 94% above that value.

What is the intrinsic value of SERA?

$1.03 per share (as of the 2026-11-17 close), against a market price of $2.00. That is a margin of safety of -94.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.